An observational study in Heart Failure, Sarcopenia and Cachexia, sponsored by Aarhus University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-26.
Sponsored by Aarhus University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.
Among the 242 studies in Heart Failure with a site in Denmark, this one is the 25th largest by planned enrollment of the 54 observational ones that give a count, is one of 13 that started in 2020, is one of 54 observational ones, reaches primary completion later than 22 of the 59 other live ones, and was the 164th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark, Finland, Norway and 1 more country
Ages 18–99
University of Aarhus · Sites in Denmark
Ages 18+
Novo Nordisk A/S · Sites in Denmark, United States, Argentina and 24 more countries
Ages 18+
Gødstrup Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
242 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 39 · Phase 3 43 · Phase 4 15
First in 1983; this study’s year is marked. 13 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 197 across the 187 interventional studies, 213 across the 54 observational. Of the 159 that completed or were terminated, 55 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 242 have an industry lead sponsor. The 10 most frequent:
Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.
Aarhus University Hospital has 6 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04709900Copenhagen University Hospital, RigshospitaletCT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes | 2026-12 |
| NCT05104658Center for Clinical Research and PreventionHeart Rehabilitation for All | 2026-12-31 |
| NCT05063955Aarhus University HospitalMechanism of Sarcopenia in Heart Failure | 2026-12-31 |
| NCT05276219Copenhagen University Hospital, RigshospitaletDECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure | 2027-05-01 |
| NCT05834803University of AarhusEffects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients. | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 242 studies in Heart Failure with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to provide information on the interaction between socioeconomic factors, daily physical activity, nutrition and lifestyle on loss of muscle mass and muscle function in patients with heart failure.
A total of 200 consecutive heart failure patients will be included and 50 age and sex-matched individuals with no history of cardiovascular disease will serve as controls.
Baseline variables of body composition, physical capacity, daily physical activity, nutritional status, quality of life, socioeconomic status and insulin resistance will be obtained along with a skeletal muscle tissue biopsy and blood samples for laboratory analyses.
Baseline variables from heart failure patients will be compared to healthy controls.
Patients and controls will be invited to follow-up visits at 12 and 36 months. Changes in baseline variables will be analyzed.
Events will be identified through national registries.
A total of 200 consecutive heart failure patients will be included and 50 age and sex matched individuals with no history of cardiovascular disease will serve as controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.
Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.
Physical performance, peak VO2
Change in peak oxygen uptake (peak VO2), measured in ml O2/kg/min
Time frame: From baseline to 12 and 36 months
Physical performance, walking distance
Change in walking distance (6MWT) in meters
Time frame: From baseline to 12 and 36 months
Physical performance, muscle strength
Change in knee extension/flexion isokinetic strength (assessed by peak torque, Nm) and isometric strength (assessed by peak torque, Nm)
Time frame: From baseline to 12 and 36 months
Cardiovascular events
Incidence of a composite endpoint of death, hospitalization with worsening of heart failure other cardiovascular events (myocardial infarction, unstable angina, revascularization and stroke) and non-cardiovascular hospitalizations
Time frame: During follow-up of 10 years
Body composition
Change in appendicular lean mass (measured in grams) and fat mass (measured in grams)
Time frame: From baseline to 12 and 36 months
Muscle tissue fiber types
Change in ratio between muscle fiber types (type I, IIa and IIb) assessed by immunohistochemistry
Time frame: From baseline to 12 and 36 months
Muscle tissue cellular composition
Change in muscle tissue cellular composition assessed by cell sorting
Time frame: From baseline to 12 and 36 months
Muscle tissue mitochondrial function
Change in muscle mitochondrial function assessed by high-resolution respirometry
Time frame: From baseline to 12 and 36 months
Daily physical activity
Change in daily physical activity assessed by 7-day accelerometry
Time frame: From baseline to 12 and 36 months
Insulin resistance
Changes in insulin resistance assessed by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Time frame: From baseline to 12 and 36 months
Whole body metabolism
Changes in circulating metabolic markers
Time frame: From baseline to 12 and 36 months
Muscle metabolism
Changes in metabolic signature of muscle tissue assessed by liquid chromatography-high-resolution mass spectrometry
Time frame: From baseline to 12 and 36 months
Symptoms
Changes in the Minnesota Living with Heart Failure Questionnaire score (range 0-105, from best to worst)
Time frame: From baseline to 12 and 36 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2020 (actual). Primary completion is estimated for Dec 2026, 72 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 72 months is above that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.